Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paola Ghanem

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Clinical Lung Cancer|August 31, 2022
Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung CancerMatthew Z Guo, Joseph C Murray, Paola Ghanem, et al.
RMD Open|November 1, 2023
Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseasesPaola Ghanem, Joseph C Murray, Kristen A Marrone, et al.
Pharmacological Reports : PR|October 8, 2020
Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK-3βHisham F Bahmad, Reda M Chalhoub, Hayat Harati, et al.
Journal of Neuro-Oncology|July 16, 2025
Distinct size and spatial distribution patterns of ALK-inhibitor-naïve versus ALK-inhibitor exposed ALK-positive NSCLC brain metastasesTia Cheunkarndee, Zsombor Ritter, Max Saint-Germain, et al.
Cancer Research Communications|February 26, 2024
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLCMari Nakazawa, Guilherme Harada, Paola Ghanem, et al.
Cancer Research|September 8, 2022
Genomic Landscapes and Hallmarks of Mutant RAS in Human CancersRobert B Scharpf, Archana Balan, Biagio Ricciuti, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Clinical Lung Cancer|August 31, 2022
Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung CancerMatthew Z Guo, Joseph C Murray, Paola Ghanem, et al.
RMD Open|November 1, 2023
Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseasesPaola Ghanem, Joseph C Murray, Kristen A Marrone, et al.
Pharmacological Reports : PR|October 8, 2020
Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK-3βHisham F Bahmad, Reda M Chalhoub, Hayat Harati, et al.
Journal of Neuro-Oncology|July 16, 2025
Distinct size and spatial distribution patterns of ALK-inhibitor-naïve versus ALK-inhibitor exposed ALK-positive NSCLC brain metastasesTia Cheunkarndee, Zsombor Ritter, Max Saint-Germain, et al.
Cancer Research Communications|February 26, 2024
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLCMari Nakazawa, Guilherme Harada, Paola Ghanem, et al.
Cancer Research|September 8, 2022
Genomic Landscapes and Hallmarks of Mutant RAS in Human CancersRobert B Scharpf, Archana Balan, Biagio Ricciuti, et al.
Pageof 2